ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 337

Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability

E Siris1, N Pannacciulli2, PD Miller3, EM Lewiecki4, R Chapurlat5, E Jódar-Gimeno6, NS Daizadeh2, RB Wagman2 and JA Kanis7, 1Columbia University Medical Center, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3Colorado Center for Bone Research, Lakewood, CO, 4New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 5Hôpital Edouard Herriot, Lyon, France, 6Hospital Universitario Quirónsalud Madrid, Madrid, Spain, 7University of Sheffield, Sheffield, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: denosumab, fractures, osteoporosis and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture.  The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the efficacy and safety of denosumab for up to 10 years.  The lack of a long-term control group in the Extension, however, limits the ability to evaluate long-term efficacy.  We used two approaches to put denosumab’s 10-year anti-fracture efficacy into perspective.  First, we compared the 10‑year observed cumulative incidence of major osteoporotic (MOP; hip, clinical spine, forearm, or humerus) and hip fracture in subjects who completed the Extension with the 10-year fracture probability predicted at baseline by FRAX (a computer-based algorithm assessing fracture probability from clinical risk factors).1  The 10-year MOP fracture rate was also compared with that estimated for a hypothetical cohort of 10‑year placebo controls (virtual twins).

Methods:  Subjects in this analysis received 10 years of denosumab (3 years FREEDOM; 7 years Extension; 60 mg Q6M), completed the 10-year visit, and missed ≤1 dose in FREEDOM and ≤1 dose in the Extension (n=1,278).  Kaplan-Meier estimates of cumulative 10-year incidence of MOP and hip fracture were determined.  Ten-year probability of fracture predicted by FRAX (calculated with femoral neck BMD) at FREEDOM baseline was also estimated.  Rate of MOP fracture in a hypothetical cohort of 10-year placebo controls (virtual twins) was estimated using a previously described simulation method and baseline characteristics identical to the 10-year denosumab completer group.2,3  

Results:  The observed cumulative 10-year fracture incidence (95% CI) was lower than the 10‑year mean (SD) fracture probability predicted by FRAX for both MOP (10.75% [9.05%–12.46%] vs 16.42% [9.06%]; Figure) and hip (1.17% [0.58%–1.76%] vs 6.14% [6.52%]) fractures.  The observed cumulative 10-year MOP fracture incidence was also significantly lower than the estimated virtual twins fracture rate (10.75% [9.05%–12.46%] vs 23.13% [17.76%–28.87%]; RR=0.49 [0.36–0.64]).  

Conclusion:  Fracture incidence with 10 years of denosumab treatment in postmenopausal women with osteoporosis was lower than the 10-year probability predicted by FRAX for both MOP and hip fractures.  It was also lower than the fracture rate estimated in a hypothetical cohort of 10-year placebo controls for MOP fracture.  These data support the long-term efficacy of denosumab in reducing MOP and hip fractures. References:  1https://www.shef.ac.uk/FRAX/index.aspx; 2Vittinghoff Stat Med 2010; 3Papapoulos Osteoporos Int 2015

 


Disclosure: E. Siris, Amgen, Merck, Radius, 5; N. Pannacciulli, Amgen Inc., 1,Amgen Inc., 3; P. Miller, Alexion, Amgen, Boehringer Ingelheim, Immunodiagnostics, Eli Lilly & Company, Merck, Merck Serrano, National Bone Health Alliance, Novartis, Radius Pharma, Roche Diagnostics, Regeneron, Daiichi Sankyo, Inc., Ultragenyx, 2,Amgen, AgNovos, Lilly, Merck, Radius Pharma, Roche, Ultragenyx, 9,Allergan Pharmaceuticals, Grunenthal Group, 9; E. Lewiecki, Amgen, Merck, Lilly, 2,Amgen, Merck, Lilly, Shire, Alexion, 5,Shire, 8; R. Chapurlat, Amgen, Merck, Chugai, 2,Amgen, Lilly, BMS, Abbvie, Pfizer, Chugai, 5; E. Jódar-Gimeno, Amgen, MSD, 2,Amgen, Lilly, MSD, 5,Amgen, Lilly, 8; N. Daizadeh, Amgen Inc., 1,Amgen Inc., 3; R. Wagman, Amgen, 1,Amgen, 3; J. Kanis, None.

To cite this abstract in AMA style:

Siris E, Pannacciulli N, Miller P, Lewiecki E, Chapurlat R, Jódar-Gimeno E, Daizadeh N, Wagman R, Kanis J. Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/denosumab-treatment-for-10-years-in-postmenopausal-women-with-osteoporosis-was-associated-with-substantially-lower-fracture-incidence-relative-to-their-baseline-frax-predicted-probability/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/denosumab-treatment-for-10-years-in-postmenopausal-women-with-osteoporosis-was-associated-with-substantially-lower-fracture-incidence-relative-to-their-baseline-frax-predicted-probability/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology